![Helen Ho](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Helen Ho
Corporate Officer/Principal chez
PARABILIS MEDICINES, INC.
Profil
Helen Ho is Chief Business & Strategy Officer at Parabilis Medicines, Inc. since 2026.
Former roles include Chief Business Officer at Blueprint Medicines Corp.
from 2022 to 2025, Director-Business Development & Operations at Agios Pharmaceuticals, Inc., and Vice President & Head-Corporate Development at TCR² Therapeutics, Inc. Education includes a doctorate from Yale University and an undergraduate degree from the University of California Los Angeles Graduate School.
Postes actifs de Helen Ho
| Sociétés | Poste | Début |
|---|---|---|
| PARABILIS MEDICINES, INC. | Corporate Officer/Principal | 10/04/2026 |
Anciens postes connus de Helen Ho
| Sociétés | Poste | Fin |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Corporate Officer/Principal | 01/01/2025 |
| AGIOS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| TCR2 THERAPEUTICS INC. | Corporate Officer/Principal | - |
Formation de Helen Ho
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
37
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Agios Pharmaceuticals, Inc.
 Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Parabilis Medicines
 Parabilis Medicines Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for cancers and tumors | Health Technology |
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy | Health Technology |
University of California Los Angeles Graduate School
 University of California Los Angeles Graduate School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
